Yahoo
NasdaqGS - Delayed Quote USD

Zenas BioPharma, Inc. (ZBIO)

19.32 +1.77 (+10.09%)
At close: April 30 at 4:00:00 PM EDT
19.49 +0.17 (+0.86%)
Pre-Market: 8:15:53 AM EDT
Trade ZBIO on Coinbase
Chart Range Bar
Loading chart for ZBIO
  • Previous Close 17.55
  • Open 19.00
  • Bid 19.23 x 100
  • Ask 19.38 x 100
  • Day's Range 18.20 - 19.48
  • 52 Week Range 8.51 - 44.60
  • Volume 686,235
  • Avg. Volume 770,656
  • Market Cap (intraday) 1.205B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -8.44
  • Earnings Date (est.) May 14, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 42.00

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

zenasbio.com

167

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: ZBIO

Trailing total returns as of 4/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ZBIO
46.79%
S&P 500 (^GSPC)
5.31%

1-Year Return

ZBIO
66.84%
S&P 500 (^GSPC)
29.45%

3-Year Return

ZBIO
5.29%
S&P 500 (^GSPC)
72.90%

5-Year Return

ZBIO
5.29%
S&P 500 (^GSPC)
72.42%

Earnings Trends: ZBIO

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -73.66M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-60M
-40M
-20M
0

Analyst Insights: ZBIO

View More

Analyst Price Targets

21.00
42.00 Average
19.32 Current
55.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/17/2026
Analyst Citigroup
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 43 -> 41

Statistics: ZBIO

View More

Valuation Measures

Annual
As of 3/20/2026
  • Market Cap

    1.20B

  • Enterprise Value

    861.27M

  • Trailing P/E

    1.62

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    86.28

  • Price/Book (mrq)

    4.97

  • Enterprise Value/Revenue

    86.13

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -35.06%

  • Return on Equity (ttm)

    -136.22%

  • Revenue (ttm)

    10M

  • Net Income Avi to Common (ttm)

    -377.74M

  • Diluted EPS (ttm)

    -8.44

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    343.19M

  • Total Debt/Equity (mrq)

    0.55%

  • Levered Free Cash Flow (ttm)

    -143.1M

Compare To: ZBIO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: ZBIO

Fair Value

19.32 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports: ZBIO

View More
  • Daily – Vickers Top Insider Picks for 04/01/2026

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

  • Daily – Vickers Top Insider Picks for 03/31/2026

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

  • Daily – Vickers Top Insider Picks for 03/30/2026

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

  • Daily – Vickers Top Insider Picks for 03/27/2026

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: